Ost-müük Quince Therapeuticks Inc - QNCX CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Hinnavahe | 0.0328 | ||||||||
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.024874% | ||||||||
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.002651% | ||||||||
Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
Min kauplemise kogus | 1 | ||||||||
Valuuta | USD | ||||||||
Tagatis | 20% | ||||||||
Aktsiabörs | United States of America | ||||||||
Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Eelmine sulgemine* | 1.5486 |
Avatud* | 1.4886 |
Aastane muutus* | -75.76% |
Päeva ulatus* | 1.4886 - 1.5586 |
52 nädala ulatus | 0.54-6.80 |
Keskmine maht (10 päeva) | 5.94M |
Keskmine maht (3 kuud) | 47.55M |
Turukapitalisatsioon | 55.87M |
P/E suhtarv | -100.00K |
Ringluses olevad aktsiad | 36.28M |
Tulu | N/A |
EPS | -1.61 |
Dividendid (% kasumist) | N/A |
Beeta | 1.31 |
Järgmine tuluaruande kuupäev | N/A |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
---|---|---|---|---|---|---|
Mar 31, 2023 | 1.5486 | 0.0600 | 4.03% | 1.4886 | 1.5686 | 1.4886 |
Mar 30, 2023 | 1.5486 | 0.0500 | 3.34% | 1.4986 | 1.5686 | 1.4886 |
Mar 29, 2023 | 1.5386 | 0.0499 | 3.35% | 1.4887 | 1.5686 | 1.4687 |
Mar 28, 2023 | 1.4687 | 0.0100 | 0.69% | 1.4587 | 1.5186 | 1.4487 |
Mar 27, 2023 | 1.4487 | 0.0200 | 1.40% | 1.4287 | 1.5486 | 1.4287 |
Mar 24, 2023 | 1.4587 | 0.0600 | 4.29% | 1.3987 | 1.4787 | 1.3488 |
Mar 23, 2023 | 1.3588 | -0.0899 | -6.21% | 1.4487 | 1.4687 | 1.3488 |
Mar 22, 2023 | 1.4187 | 0.0200 | 1.43% | 1.3987 | 1.4687 | 1.3688 |
Mar 21, 2023 | 1.4187 | 0.0000 | 0.00% | 1.4187 | 1.5186 | 1.3388 |
Mar 20, 2023 | 0.8196 | 0.0004 | 0.05% | 0.8192 | 0.8360 | 0.7892 |
Mar 17, 2023 | 0.8188 | -0.0171 | -2.05% | 0.8359 | 0.8359 | 0.7848 |
Mar 16, 2023 | 0.8193 | -0.0066 | -0.80% | 0.8259 | 0.8557 | 0.7919 |
Mar 15, 2023 | 0.8410 | -0.0382 | -4.34% | 0.8792 | 0.8792 | 0.8155 |
Mar 14, 2023 | 0.8716 | -0.0339 | -3.74% | 0.9055 | 0.9155 | 0.8691 |
Mar 13, 2023 | 0.8791 | -0.0663 | -7.01% | 0.9454 | 0.9454 | 0.8656 |
Mar 10, 2023 | 0.9237 | -0.0326 | -3.41% | 0.9563 | 0.9752 | 0.9237 |
Mar 9, 2023 | 0.9743 | -0.0247 | -2.47% | 0.9990 | 1.0490 | 0.9643 |
Mar 8, 2023 | 0.9832 | 0.0080 | 0.82% | 0.9752 | 0.9950 | 0.9393 |
Mar 7, 2023 | 0.9591 | 0.0079 | 0.83% | 0.9512 | 0.9784 | 0.9491 |
Mar 6, 2023 | 0.9667 | 0.0023 | 0.24% | 0.9644 | 0.9868 | 0.9433 |
Quince Therapeuticks Inc Events
Kellaaeg (UTC) (UTC) | Riik | Sündmus |
---|---|---|
No events scheduled |
- Aastas
- Kvartalis
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Kogutulu | 0 | 0 | 0 | 0 | 0 |
Kogu tegevuskulu | 52.015 | 90.318 | 78.893 | 39.168 | 12.119 |
Müük/Üldine/admin kulud, kokku | 26.012 | 29.523 | 17.586 | 8.954 | 2.034 |
Uuringud ja arendus | 25.178 | 60.795 | 61.307 | 30.214 | 10.085 |
Tulud majandustegevusest | -52.015 | -90.318 | -78.893 | -39.168 | -12.119 |
Intressitulud (kulu), muud tulud, neto | 1.068 | 0.62 | 2.044 | 2.188 | -0.357 |
Netotulu enne makse | -51.944 | -89.945 | -76.849 | -36.98 | -12.476 |
Netotulu pärast makse | -51.66 | -89.945 | -76.849 | -36.98 | -12.476 |
Netotulu enne erikulusid | -51.66 | -89.945 | -76.849 | -36.98 | -12.476 |
Erakorralised kulud kokku | |||||
Netotulu | -51.66 | -89.945 | -76.849 | -36.98 | -12.476 |
Arvestatav tulu, v a erikulud | -51.66 | -89.945 | -76.849 | -36.98 | -12.476 |
Arvestatav tulu, koos erikuludega | -51.66 | -89.945 | -76.849 | -36.98 | -12.476 |
Jaotamisele kuuluv netotulu | -51.66 | -89.945 | -76.849 | -36.98 | -12.476 |
Keskmine jaotamisele kuuluv aktsia kohta | 33.4965 | 29.7185 | 29.1762 | 19.0319 | 26.0133 |
Jaotatav EPS, v a erakorralised kulud | -1.54225 | -3.02657 | -2.63396 | -1.94305 | -0.4796 |
Dividends per Share - Common Stock Primary Issue | 0 | ||||
Jaotamisele kuuluv normaal-EPS | -1.52624 | -3.02657 | -2.63396 | -1.94305 | -0.4796 |
Muud, neto | -0.997 | -0.247 | |||
Ootamatud kulutused (tulu) | 0.825 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
Kogutulu | 0 | 0 | 0 | 0 | 0 |
Kogu tegevuskulu | 6.319 | 7.62 | 16.258 | 21.863 | 23.544 |
Müük/Üldine/admin kulud, kokku | 3.551 | 4.344 | 9.059 | 9.106 | 8.331 |
Uuringud ja arendus | 2.768 | 2.451 | 7.199 | 12.757 | 15.213 |
Tulud majandustegevusest | -6.319 | -7.62 | -16.258 | -21.863 | -23.544 |
Intressitulud (kulu), muud tulud, neto | 0.536 | 0.315 | 0.145 | 0.072 | 0.105 |
Netotulu enne makse | -5.534 | -7.921 | -16.848 | -21.641 | -23.399 |
Netotulu pärast makse | -5.534 | -7.921 | -16.564 | -21.641 | -23.399 |
Netotulu enne erikulusid | -5.534 | -7.921 | -16.564 | -21.641 | -23.399 |
Netotulu | -5.534 | -7.921 | -16.564 | -21.641 | -23.399 |
Arvestatav tulu, v a erikulud | -5.534 | -7.921 | -16.564 | -21.641 | -23.399 |
Arvestatav tulu, koos erikuludega | -5.534 | -7.921 | -16.564 | -21.641 | -23.399 |
Jaotamisele kuuluv netotulu | -5.534 | -7.921 | -16.564 | -21.641 | -23.399 |
Keskmine jaotamisele kuuluv aktsia kohta | 35.7117 | 35.6128 | 32.467 | 30.1345 | 29.962 |
Jaotatav EPS, v a erakorralised kulud | -0.15496 | -0.22242 | -0.51018 | -0.71815 | -0.78095 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
Jaotamisele kuuluv normaal-EPS | -0.15496 | -0.19925 | -0.51018 | -0.71815 | -0.78095 |
Muud, neto | 0.249 | -0.616 | -0.735 | 0.15 | 0.04 |
Ootamatud kulutused (tulu) | 0 | 0.825 |
- Aastas
- Kvartalis
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Käibevarad kokku | 111.673 | 137.862 | 106.056 | 72.584 | 7.537 |
Raha ja lühiajalised investeeringud | 106.802 | 133.82 | 99.864 | 71.716 | 7.343 |
Cash | 40.27 | 35.69 | 4.074 | 11.259 | 7.343 |
Raha ja ekvivalendid | 15.954 | 16.151 | 46.155 | 11.815 | 0 |
Lühiajalised investeeringud | 50.578 | 81.979 | 49.635 | 48.642 | 0 |
Prepaid Expenses | 3.376 | 3.348 | 5.504 | 0.766 | 0.141 |
Other Current Assets, Total | 1.495 | 0.694 | 0.688 | 0.102 | 0.053 |
Total Assets | 133.228 | 189.466 | 124.37 | 72.877 | 7.718 |
Property/Plant/Equipment, Total - Net | 1.428 | 1.101 | 1.334 | 0.283 | 0.122 |
Property/Plant/Equipment, Total - Gross | 2.387 | 1.716 | 1.617 | 0.378 | 0.166 |
Accumulated Depreciation, Total | -0.959 | -0.615 | -0.283 | -0.095 | -0.044 |
Other Long Term Assets, Total | 0.194 | 0.039 | 0.217 | 0.01 | 0.059 |
Total Current Liabilities | 14.222 | 16.996 | 8.892 | 1.457 | 1.763 |
Accounts Payable | 4.911 | 3.555 | 3.075 | 0.495 | 0.517 |
Accrued Expenses | 9.311 | 13.441 | 5.817 | 0.962 | 1.246 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 14.642 | 17.204 | 8.892 | 1.457 | 10.82 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 7.171 |
Long Term Debt | 0 | 7.171 | |||
Other Liabilities, Total | 0.42 | 0.208 | 0 | 1.886 | |
Total Equity | 118.586 | 172.262 | 115.478 | 71.42 | -3.102 |
Redeemable Preferred Stock | 0 | 104.046 | 17.178 | ||
Common Stock | 0.03 | 0.029 | 0.027 | 0.009 | 0.009 |
Additional Paid-In Capital | 355.234 | 318.574 | 185.196 | 0.239 | 0.06 |
Retained Earnings (Accumulated Deficit) | -236.599 | -146.654 | -69.805 | -32.825 | -20.349 |
Other Equity, Total | -0.079 | 0.313 | 0.06 | -0.049 | 0 |
Total Liabilities & Shareholders’ Equity | 133.228 | 189.466 | 124.37 | 72.877 | 7.718 |
Total Common Shares Outstanding | 30.0744 | 29.5432 | 26.8694 | 26.0133 | 26.0133 |
Long Term Investments | 19.933 | 50.464 | 16.763 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Käibevarad kokku | 96.353 | 111.673 | 119.427 | 135.843 | 149.885 |
Raha ja lühiajalised investeeringud | 91.524 | 106.802 | 114.412 | 129.95 | 147.035 |
Cash | 27.403 | 40.27 | 8.357 | 5.744 | 24.569 |
Raha ja ekvivalendid | 32.361 | 15.954 | 36.6 | 47.049 | 38.246 |
Lühiajalised investeeringud | 31.76 | 50.578 | 69.455 | 77.157 | 84.22 |
Prepaid Expenses | 2.784 | 3.376 | 4.52 | 5.455 | 2.293 |
Other Current Assets, Total | 2.045 | 1.495 | 0.495 | 0.438 | 0.557 |
Total Assets | 116.13 | 133.228 | 147.416 | 161.39 | 174.522 |
Property/Plant/Equipment, Total - Net | 0.573 | 1.428 | 1.655 | 1.886 | 0.878 |
Property/Plant/Equipment, Total - Gross | 1.569 | 2.387 | 2.53 | 2.674 | 1.579 |
Accumulated Depreciation, Total | -0.996 | -0.959 | -0.875 | -0.788 | -0.701 |
Long Term Investments | 19.175 | 19.933 | 26.141 | 23.516 | 23.72 |
Other Long Term Assets, Total | 0.029 | 0.194 | 0.193 | 0.145 | 0.039 |
Total Current Liabilities | 9.71 | 14.222 | 14.154 | 18.537 | 17.867 |
Accounts Payable | 3.731 | 4.911 | 2.88 | 7.193 | 2.845 |
Accrued Expenses | 5.979 | 9.311 | 11.274 | 11.344 | 15.022 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 9.75 | 14.642 | 14.764 | 19.31 | 18.038 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 0.04 | 0.42 | 0.61 | 0.773 | 0.171 |
Total Equity | 106.38 | 118.586 | 132.652 | 142.08 | 156.484 |
Common Stock | 0.03 | 0.03 | 0.03 | 0.03 | 0.029 |
Additional Paid-In Capital | 365.096 | 355.234 | 345.751 | 333.427 | 326.006 |
Retained Earnings (Accumulated Deficit) | -258.24 | -236.599 | -213.2 | -191.494 | -169.74 |
Other Equity, Total | -0.506 | -0.079 | 0.071 | 0.117 | 0.189 |
Total Liabilities & Shareholders’ Equity | 116.13 | 133.228 | 147.416 | 161.39 | 174.522 |
Total Common Shares Outstanding | 30.1496 | 30.0744 | 29.8673 | 29.6558 | 29.5759 |
- Aastas
- Kvartalis
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Netotulu/algväärtus | -89.945 | -76.849 | -36.98 | -12.476 | -12.235 |
Raha majandustegevusest | -62.932 | -50.818 | -33.277 | -11.695 | -9.827 |
Raha majandustegevusest | 0.344 | 0.332 | 0.188 | 0.051 | 0.045 |
Mittelikviidsed varad | 30.93 | 15.472 | 1.611 | 1.12 | 1.903 |
Makstud intressid | 0.001 | 0.001 | |||
Muutused tööjõus | -4.261 | 10.227 | 1.904 | -0.39 | 0.46 |
Tulu investeeringutelt | 58.952 | -52.431 | -17.747 | -46.754 | -0.077 |
Kapitalikulutused | -0.18 | -0.052 | -0.055 | -0.212 | -0.077 |
Muud rahavood investeeringutelt, kokku | 59.132 | -52.379 | -17.692 | -46.542 | 0 |
Rahavood investeeringutelt | 6.808 | 118.876 | 77.366 | 75.928 | 7.75 |
Aktsiate emiteerimine (tagasiost), neto | 6.808 | 118.91 | 77.925 | 75.678 | 0 |
Laenu väljastamine (kustutamine), neto | 0 | -0.034 | -0.559 | 0.25 | 7.75 |
Rahaline kogumuutus | 2.883 | 15.627 | 26.342 | 17.479 | -2.154 |
Muutused valuutakursside kõikumisest | 0.055 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -21.641 | -89.945 | -66.546 | -44.84 | -23.086 |
Cash From Operating Activities | -16.091 | -62.932 | -48.514 | -31.172 | -13.61 |
Cash From Operating Activities | 0.038 | 0.344 | 0.26 | 0.173 | 0.086 |
Non-Cash Items | 9.375 | 30.93 | 22.238 | 14.371 | 7.285 |
Changes in Working Capital | -3.863 | -4.261 | -4.466 | -0.876 | 2.105 |
Cash From Investing Activities | 13.413 | 58.952 | 38.033 | 37.267 | 31.643 |
Capital Expenditures | -0.005 | -0.18 | -0.136 | -0.136 | -0.037 |
Other Investing Cash Flow Items, Total | 13.418 | 59.132 | 38.169 | 37.403 | 31.68 |
Cash From Financing Activities | 0.622 | 6.808 | 5.818 | 1.113 | 0.441 |
Issuance (Retirement) of Stock, Net | 0.622 | 6.808 | 5.818 | 1.113 | 0.441 |
Net Change in Cash | -2.16 | 2.883 | -4.634 | 7.208 | 18.474 |
Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | ||
Foreign Exchange Effects | -0.104 | 0.055 | 0.029 |
Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
---|---|---|---|---|---|---|
Lamond (David A.) | Individual Investor | 10.1543 | 3683658 | 1634720 | 2022-01-31 | |
Dominy (Stephen S) | Individual Investor | 3.9631 | 1437674 | 763 | 2022-01-31 | |
Lynch (Casey C) | Individual Investor | 3.2544 | 1180580 | -120000 | 2022-01-31 | |
EPIQ Capital Group, LLC | Investment Advisor | 2.9115 | 1056191 | -1000478 | 2022-12-31 | LOW |
Two Sigma Investments, LP | Hedge Fund | 2.4701 | 896084 | -61145 | 2022-12-31 | HIGH |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.3524 | 853391 | -18615 | 2022-12-31 | LOW |
Pfizer Inc | Corporation | 1.6539 | 600000 | -1456377 | 2021-12-31 | MED |
Millennium Management LLC | Hedge Fund | 1.6424 | 595801 | 137810 | 2022-12-31 | HIGH |
Low (Philip S) | Individual Investor | 1.2551 | 455309 | 455309 | 2022-05-19 | |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.9169 | 332627 | -165208 | 2022-12-31 | LOW |
Thye (Dirk) | Individual Investor | 0.7744 | 280911 | 280911 | 2022-05-19 | |
Lowe (Christopher P) | Individual Investor | 0.7305 | 265000 | 175000 | 2022-03-03 | LOW |
Federated Hermes MDTA LLC | Investment Advisor/Hedge Fund | 0.6904 | 250458 | -264583 | 2022-12-31 | HIGH |
Smith (Karen L) | Individual Investor | 0.5367 | 194690 | 194690 | 2022-05-19 | LOW |
Alphabet, Inc. | Venture Capital | 0.5213 | 189122 | 0 | 2022-12-31 | LOW |
Renaissance Technologies LLC | Hedge Fund | 0.4248 | 154100 | -180125 | 2022-12-31 | HIGH |
Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 0.4239 | 153788 | 0 | 2022-12-31 | MED |
Holsinger (Leslie) | Individual Investor | 0.3985 | 144580 | -10920 | 2022-06-06 | |
Detke (Michael J) | Individual Investor | 0.3859 | 140000 | 140000 | 2022-03-03 | |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.3779 | 137086 | -9128 | 2022-12-31 | LOW |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group500K+
Kauplejad
92K+
Igakuiste aktiivsete klientide arv
$53M+
Igakuine investeerimise maht
$30M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Cortexyme Inc. Company profile
Ettevõttest Cortexyme, Inc.
Cortexyme, Inc. on kliinilises staadiumis biofarmatseutiline ettevõte, mis keskendub Alzheimeri tõve ja teiste degeneratiivsete haiguste raviks mõeldud haigusi modifitseerivate ravimite pakkumisele. Ettevõte pakub 3CLpro inhibiitorit, COR803 toodet, mis on juhtiv ühend koronaviirusinfektsioonide raviks. Ettevõtte tooteprogrammi kuuluvad ravimikandidaadid kesknärvisüsteemi (KNS) haiguste, sealhulgas Alzheimeri tõve raviks; onkoloogiliste rakenduste raviks, sealhulgas suu limaskesta kartsinoomi ennetamiseks, ning vähekasutatavate ja krooniliste haiguste, näiteks parodontiidi raviks. Ettevõtte COR388 on mõeldud Alzheimeri tõve ja Parkinsoni tõve raviks. Ettevõtte COR588 on I faasi kliinilises uuringus ja on suunatud parodontiidi ja muude P. gingivalisega seotud näidustuste raviks. Ettevõte arendab ka COR588, mis on teise põlvkonna aju läbiv lüsiini gingipaiini inhibiitor.
Industry: | Biotechnology & Medical Research (NEC) |
269 East Grand Ave
94080
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 500,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com